Reuters -- Merck & Co Inc shares fell 3.8 percent on Thursday amid speculation its Zetia cholesterol medicine fared poorly in a clinical trial comparing it with Abbott Laboratories’ Niaspan in preventing plaque build-up in arteries.
Reuters -- Merck & Co Inc shares fell 3.8 percent on Thursday amid speculation its Zetia cholesterol medicine fared poorly in a clinical trial comparing it with Abbott Laboratories’ Niaspan in preventing plaque build-up in arteries.
